We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Internal Medicine

Internal Medicine

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

The Hidden Purines in Plant-Based Diets: What High Uric Acid Patients Need to Know
Family Medicine & Nutritiongouthealth management

The Hidden Purines in Plant-Based Diets: What High Uric Acid Patients Need to Know

By MedXY|Oct 9, 2025

High uric acid is linked to several diseases, and many avoid meat fearing purines. However, some vegetarian foods are high in purines too. Understanding these can help better manage uric acid levels and prevent complications like gout.

Rapirosiran: A Promising RNA Interference Therapy Targeting HSD17B13 for Metabolic Dysfunction-Associated Steatohepatitis
Clinical UpdatesHSD17B13MASH

Rapirosiran: A Promising RNA Interference Therapy Targeting HSD17B13 for Metabolic Dysfunction-Associated Steatohepatitis

By MedXY|Oct 8, 2025

This phase I randomized study shows rapirosiran, an RNAi therapeutic targeting HSD17B13, is safe and effectively reduces liver HSD17B13 mRNA in patients with metabolic dysfunction-associated steatohepatitis (MASH).

Enhancing Fibrosis Scoring in MASH: The Role of AI-Enhanced Digital Pathology
AIclinical trialsfibrosis

Enhancing Fibrosis Scoring in MASH: The Role of AI-Enhanced Digital Pathology

By MedXY|Oct 8, 2025

AI-assisted digital pathology improves inter-pathologist agreement on fibrosis staging in metabolic dysfunction-associated steatohepatitis (MASH), enhancing clinical trial accuracy and efficiency.

HEC88473 Dual GLP-1/FGF21 Agonist: Advancing Treatment for MASLD and T2DM with Promising Safety and Efficacy
Clinical UpdatesFGF21GLP-1

HEC88473 Dual GLP-1/FGF21 Agonist: Advancing Treatment for MASLD and T2DM with Promising Safety and Efficacy

By MedXY|Oct 8, 2025

A phase Ib/IIa trial demonstrated that HEC88473, a novel GLP-1/FGF21 dual agonist, is generally safe, effectively reduces liver fat, and improves glycemic and lipid profiles in MASLD patients with type 2 diabetes within five weeks of treatm

AZD2693: Targeting PNPLA3 148M Variant as a Precision Therapy for Metabolic Steatohepatitis
Clinical UpdatesAntisense oligonucleotideMASH

AZD2693: Targeting PNPLA3 148M Variant as a Precision Therapy for Metabolic Steatohepatitis

By MedXY|Oct 8, 2025

AZD2693, a liver-directed antisense oligonucleotide, safely reduces PNPLA3 expression and liver fat in homozygous PNPLA3 148M carriers with metabolic dysfunction-associated steatohepatitis, signaling promise for precision treatment in this

Rapirosiran: A Promising RNAi Therapy Targeting HSD17B13 in Metabolic Dysfunction-Associated Steatohepatitis
Clinical UpdatesHSD17B13metabolic dysfunction-associated steatohepatitis

Rapirosiran: A Promising RNAi Therapy Targeting HSD17B13 in Metabolic Dysfunction-Associated Steatohepatitis

By MedXY|Oct 8, 2025

This phase I study evaluates rapirosiran, an RNA interference therapeutic targeting HSD17B13, demonstrating safety, tolerability, and significant liver mRNA reduction in patients with metabolic dysfunction-associated steatohepatitis (MASH).

Pan-PPAR Agonist Lanifibranor: A Breakthrough in Improving Insulin Resistance and Hepatic Steatosis in T2D and MASLD Patients
Clinical Updateshepatic steatosisinsulin resistance

Pan-PPAR Agonist Lanifibranor: A Breakthrough in Improving Insulin Resistance and Hepatic Steatosis in T2D and MASLD Patients

By MedXY|Oct 8, 2025

Lanifibranor, a pan-PPAR agonist, significantly reduces liver fat and improves insulin sensitivity at multiple tissue sites in type 2 diabetes patients with MASLD, offering a new therapeutic avenue to address underlying metabolic dysfunctio

Icosabutate in Metabolic Dysfunction-Associated Steatohepatitis: Insights from the Phase IIb ICONA Trial
Clinical UpdatesFFAR1FFAR4

Icosabutate in Metabolic Dysfunction-Associated Steatohepatitis: Insights from the Phase IIb ICONA Trial

By MedXY|Oct 8, 2025

A phase IIb trial of the FFAR1/FFAR4 agonist icosabutate in MASH shows encouraging fibrosis improvement and biomarker responses despite not meeting the primary endpoint, supporting further development.

Icosabutate and FFAR1/FFAR4 Agonism in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Insights from the ICONA Phase IIb Trial
Clinical Updatesclinical trialFFAR1

Icosabutate and FFAR1/FFAR4 Agonism in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Insights from the ICONA Phase IIb Trial

By MedXY|Oct 8, 2025

The phase IIb ICONA trial evaluated icosabutate, a dual FFAR1/FFAR4 agonist, in patients with MASH, showing fibrosis improvement without meeting the primary endpoint, and supporting further development particularly in advanced fibrosis and

Evaluating Low-Dose Aspirin for Postpartum Venous Thromboembolism Prevention: Insights from the Pilot PARTUM Trial
Clinical Updateslow-dose aspirinrandomized trial

Evaluating Low-Dose Aspirin for Postpartum Venous Thromboembolism Prevention: Insights from the Pilot PARTUM Trial

By MedXY|Oct 8, 2025

The pilot PARTUM trial demonstrates the feasibility of a large-scale multi-national randomized study assessing low-dose aspirin versus placebo for postpartum venous thromboembolism prevention in moderate-risk individuals, supporting further

Clinical Updatestirzepatidetype 2 diabetes

Tirzepatide Influences Muscle Composition Favorably Amid Weight Loss in Type 2 Diabetes: Insights from SURPASS-3 MRI Substudy

By MedXY|Oct 8, 2025

In type 2 diabetes patients, tirzepatide treatment led to significant reductions in muscle fat infiltration and adaptive decreases in muscle volume over 52 weeks, suggesting beneficial effects on muscle health concurrent with weight loss.

High-Dose vs Standard-Dose Influenza Vaccine in Older Adults: Insights from the DANFLU-2 Randomized Clinical Trial
Clinical Updatescardiovascular outcomesinfluenza vaccine

High-Dose vs Standard-Dose Influenza Vaccine in Older Adults: Insights from the DANFLU-2 Randomized Clinical Trial

By MedXY|Oct 6, 2025

The DANFLU-2 trial demonstrates that high-dose influenza vaccine reduces cardiovascular and cardiorespiratory hospitalizations compared to standard-dose in adults ≥65 years, with similar benefits across subgroups including heart failure and

Ageing, Oral Microbiome, and Vascular Health: How Dietary Nitrate Unlocks Cardiovascular Benefits
Cardiologydietary nitrateNitric Oxide

Ageing, Oral Microbiome, and Vascular Health: How Dietary Nitrate Unlocks Cardiovascular Benefits

By MedXY|Oct 5, 2025

Dietary nitrate supplementation alters age-related oral microbiome changes, enhancing nitric oxide bioavailability and reducing blood pressure in older adults, highlighting a novel mechanism for vascular health improvement.

Unraveling Mitochondrial Dysfunction as a Key Pathological Feature in Long COVID Syndrome
Infectious DiseasesBioenergeticslong COVID

Unraveling Mitochondrial Dysfunction as a Key Pathological Feature in Long COVID Syndrome

By MedXY|Oct 5, 2025

Long COVID patients exhibit distinct mitochondrial bioenergetic impairments, with altered ATP synthase function correlating with clinical symptoms and quality of life, implicating mitochondrial dysfunction in its pathogenesis.

Thyroid Hormone Levels as Predictors of Long-Term Outcomes in Chronic Critical Illness
Clinical UpdatesChronic Critical IllnessPrognostic Model

Thyroid Hormone Levels as Predictors of Long-Term Outcomes in Chronic Critical Illness

By MedXY|Oct 5, 2025

Low FT3 and FT4 levels in chronic critical illness correlate with increased 90-day mortality, supporting thyroid function as a valuable prognostic marker and guide for early clinical intervention.

Breathing Hydrogen: How Molecular Hydrogen Inhalation Alters Resting Metabolism in Healthy Women
Family Medicine & Nutritionfat oxidation

Breathing Hydrogen: How Molecular Hydrogen Inhalation Alters Resting Metabolism in Healthy Women

By MedXY|Oct 5, 2025

A study reveals that inhaling molecular hydrogen for 60 minutes enhances fat oxidation at rest in healthy women, potentially offering metabolic benefits, particularly for those with higher body fat percentages.

Higher Calorie Intake Plus Adequate Exercise Linked to Lower Mortality Compared to Low-Calorie Diet with Exercise: Insights from NHANES Data
Clinical Updatescardiovascular healthexercise

Higher Calorie Intake Plus Adequate Exercise Linked to Lower Mortality Compared to Low-Calorie Diet with Exercise: Insights from NHANES Data

By MedXY|Oct 4, 2025

An observational study from NHANES reveals that higher calorie intake combined with adequate exercise reduces all-cause and cardiovascular mortality more than a low-calorie diet with similar exercise levels.

Dihydroberberine: Enhanced Absorption and Emerging Therapeutic Potential Based on Recent Clinical and Mechanistic Insights
Clinical UpdatesBerberinedihydroberberine

Dihydroberberine: Enhanced Absorption and Emerging Therapeutic Potential Based on Recent Clinical and Mechanistic Insights

By MedXY|Oct 4, 2025

Dihydroberberine demonstrates superior absorption compared to berberine, suggesting enhanced pharmacological properties. Recent studies highlight its potential in metabolic and inflammatory diseases, warranting further clinical exploration.

Recognizing and Mitigating Early Signs of Aging: What You Should Know
Family Medicine & Nutritionbiological aginghealth tips

Recognizing and Mitigating Early Signs of Aging: What You Should Know

By MedXY|Oct 4, 2025

Explore five common physical signs indicating the onset of aging and learn how consistent sleep habits can help slow biological aging through practical lifestyle changes.

Sitting-Rising Test and Single-Leg Balance: Simple yet Powerful Predictors of Longevity and Aging
Family Medicine & Nutritionbalancemortality risk

Sitting-Rising Test and Single-Leg Balance: Simple yet Powerful Predictors of Longevity and Aging

By MedXY|Oct 4, 2025

A simple sitting-rising test (SRT) and single-leg standing time can powerfully predict mortality risk and reflect neuromuscular aging, offering a low-cost method to assess health in middle-aged and older adults.

Prev
20 / 22
1…1819202122
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities

Browse by specialty

Open language-specific specialty feeds and department pages.

news6629 articlesCardiology1375 articlesClinical Updates1288 articlesOncology1139 articlesDiabetes & Endocrinology842 articlesNeurology820 articlesPublic Health595 articlesGastroenterology572 articles
Hematology-Oncology
487 articles
Pediatrics484 articles
Internal Medicine444 articles